BACKGROUND: Human immunodeficiency virus (HIV)-infected persons are at risk for severe influenza infections. Although vaccination against the H1N1 pandemic influenza strain is recommended, currently there are no data on the durability of post-vaccination antibody responses in this population. METHODS: HIV-infected and HIV-uninfected adults (18-50 years old) received a single dose of monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009H1N1). Antibody levels to the 2009 H1N1 pandemic strain were determined at day 0, day 28, and 6 months by hemagglutination-inhibition assay. A seroprotective response was a post-vaccination titer of ≥1:40 among those with a pre-vaccination level of ≤1:10. Geometric mean titers (GMT) and factors associated with higher levels were also evaluated. RESULTS: We studied 127 participants with a median age of 35 (interquartile range (IQR) 28, 42) years. Among the HIV-infected arm (n=63), the median CD4 count was 595 (IQR 476, 819)cells/mm(3) and 83% were receiving HAART. Thirty-five percent of all participants had a pre-vaccination level of >1:10. HIV-infected compared to HIV-uninfected adults were less likely to generate a seroprotective response at day 28 (54% vs. 75%, adjusted OR 0.23, p=0.021) or have a durable response at 6 months post-vaccination (28% vs. 56%, adjusted OR 0.19, p=0.005). Additionally, although pre-vaccination GMT were similar in both arms (median 7 vs. 8, p=0.11), the GMT at 6 months was significantly lower among HIV-infected versus HIV-uninfected adults (median 20 vs. 113, p=0.003). Among HIV-infected persons, younger age (p=0.035) and receipt of HAART (p=0.028) were associated with higher GMTs at 6 months. CONCLUSIONS: Despite vaccination, most HIV-infected adults do not generate durable seroprotective antibody responses to the 2009 influenza A (H1N1) virus, and hence may remain vulnerable to infection. In addition to HAART use, more immunogenic vaccines are likely needed for improving protection against influenza in this population.
BACKGROUND:Human immunodeficiency virus (HIV)-infectedpersons are at risk for severe influenza infections. Although vaccination against the H1N1 pandemic influenza strain is recommended, currently there are no data on the durability of post-vaccination antibody responses in this population. METHODS:HIV-infected and HIV-uninfected adults (18-50 years old) received a single dose of monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009H1N1). Antibody levels to the 2009 H1N1 pandemic strain were determined at day 0, day 28, and 6 months by hemagglutination-inhibition assay. A seroprotective response was a post-vaccination titer of ≥1:40 among those with a pre-vaccination level of ≤1:10. Geometric mean titers (GMT) and factors associated with higher levels were also evaluated. RESULTS: We studied 127 participants with a median age of 35 (interquartile range (IQR) 28, 42) years. Among the HIV-infected arm (n=63), the median CD4 count was 595 (IQR 476, 819)cells/mm(3) and 83% were receiving HAART. Thirty-five percent of all participants had a pre-vaccination level of >1:10. HIV-infected compared to HIV-uninfected adults were less likely to generate a seroprotective response at day 28 (54% vs. 75%, adjusted OR 0.23, p=0.021) or have a durable response at 6 months post-vaccination (28% vs. 56%, adjusted OR 0.19, p=0.005). Additionally, although pre-vaccination GMT were similar in both arms (median 7 vs. 8, p=0.11), the GMT at 6 months was significantly lower among HIV-infected versus HIV-uninfected adults (median 20 vs. 113, p=0.003). Among HIV-infectedpersons, younger age (p=0.035) and receipt of HAART (p=0.028) were associated with higher GMTs at 6 months. CONCLUSIONS: Despite vaccination, most HIV-infected adults do not generate durable seroprotective antibody responses to the 2009 influenza A (H1N1) virus, and hence may remain vulnerable to infection. In addition to HAART use, more immunogenic vaccines are likely needed for improving protection against influenza in this population.
Authors: Janice K Louie; Meileen Acosta; Kathleen Winter; Cynthia Jean; Shilpa Gavali; Robert Schechter; Duc Vugia; Kathleen Harriman; Bela Matyas; Carol A Glaser; Michael C Samuel; Jon Rosenberg; John Talarico; Douglas Hatch Journal: JAMA Date: 2009-11-04 Impact factor: 56.272
Authors: P Durando; D Fenoglio; A Boschini; F Ansaldi; G Icardi; L Sticchi; A Renzoni; P Fabbri; A Ferrera; A Parodi; B Bruzzone; G Gabutti; A Podda; G Del Giudice; E Fragapane; F Indiveri; P Crovari; R Gasparini Journal: Clin Vaccine Immunol Date: 2007-11-14
Authors: Michael L Landrum; Katherine Huppler Hullsiek; Anuradha Ganesan; Amy C Weintrob; Nancy F Crum-Cianflone; R Vincent Barthel; Sheila Peel; Brian K Agan Journal: Vaccine Date: 2009-05-03 Impact factor: 3.641
Authors: Ben S Wendel; Daniel Del Alcazar; Chenfeng He; Perla M Del Río-Estrada; Benjamas Aiamkitsumrit; Yuria Ablanedo-Terrazas; Stefany M Hernandez; Ke-Yue Ma; Michael R Betts; Laura Pulido; Jun Huang; Phyllis A Gimotty; Gustavo Reyes-Terán; Ning Jiang; Laura F Su Journal: Sci Immunol Date: 2018-04-06
Authors: Babasaheb V Tandale; Shailesh D Pawar; Yogesh K Gurav; Saurabh S Parkhi; Akhilesh C Mishra Journal: Hum Vaccin Immunother Date: 2012-10-09 Impact factor: 3.452
Authors: Patricia M Flynn; Sharon Nachman; Petronella Muresan; Terence Fenton; Stephen A Spector; Coleen K Cunningham; Robert Pass; Ram Yogev; Sandra Burchett; Barbara Heckman; Anthony Bloom; L Jill Utech; Patricia Anthony; Elizabeth Petzold; Wende Levy; George K Siberry; Ruth Ebiasah; Judi Miller; Edward Handelsman; Adriana Weinberg Journal: J Infect Dis Date: 2012-05-21 Impact factor: 5.226
Authors: Undine Ott; Andreas Sauerbrei; Jeannette Lange; Anna Schäfler; Mario Walther; Gunter Wolf; Peter Wutzler; Roland Zell; Andi Krumbholz Journal: Med Microbiol Immunol Date: 2012-02-17 Impact factor: 3.402
Authors: Claire-Anne Siegrist; Christian van Delden; Michael Bel; Christophe Combescure; Cécile Delhumeau; Matthias Cavassini; Olivier Clerc; Sara Meier; Karine Hadaya; Paola M Soccal; Sabine Yerly; Laurent Kaiser; Bernard Hirschel; Alexandra Calmy Journal: PLoS One Date: 2012-07-27 Impact factor: 3.240